Bupropion SR as an Anti-Craving Anti-Obesity Agent

描述（由申请人提供）：随着肥胖患病率的增加，现有的药物治疗仍然有一定的好处，研究控制食物摄入机制的药理学修饰是必要的。安非他酮，一种用于戒烟的抗抑郁药和抗渴望剂，已被观察到通过一种未知的机制产生体重减轻。这种化合物的临床疗效被认为是由于去甲肾上腺素能和多巴胺能活性。多巴胺在调节食物奖励中起着既定的作用。拟议研究的目的是验证安非他酮会减少超重和肥胖人类受试者的食物奖励和渴望的主要假设。为了验证这一假设，将使用喂养实验室范例，72小时饮食回忆和验证的渴望问卷。本研究结果的意义包括为现有的厌氧化合物安非他酮的潜在独特行为机制提供见解。这项研究结果的长期影响包括对这种药物作为肥胖症和暴饮暴食症等疾病的治疗干预的潜在调查。

DESCRIPTION (provided by applicant): As the prevalence of obesity increases and available pharmacotherapies remain of modest benefit, investigating the pharmacological modification of mechanisms that control food intake is imperative. Bupropion, an antidepressant and anti-craving agent for smoking cessation, has been observed to produce weight loss through an uncharacterized mechanism. The clinical efficacy of this compound is thought to result from noradrenergic and dopaminergic activity. Dopamine has an established role in modulating food reward. The objective of the proposed study is to test the primary hypothesis that bupropion will reduce food reward and craving in overweight and obese human subjects. To examine this postulate, a feeding laboratory paradigm, 72 hour dietary recall, and validated craving questionnaires will be used. Implications for the results of this study include providing insight into a potentially unique behavioral mechanism of action of the existing anorexigenic compound bupropion. Longer term implications for the results of this study include the potential investigation of this agent as a therapeutic intervention for conditions such as obesity and binge eating disorder.